Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind non-inferiority study of H077 extended-release tablets versus silodosin capsules in benign prostatic hyperplasia
CTR20253077Phase 3Active
- Sponsor
- Shanghai Huilun Pharmaceutical Co., Ltd.
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of silodosin in benign prostatic hyperplasia (BPH), sponsored by Shanghai Huilun Pharmaceutical Co., Ltd.. Started Aug 2025; status: active.
02
Drugs
silodosin
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on CTR20253077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253077.